2025-04-012026-03-312026-03-31false10105035CONTEXT THERAPY LIMITED2026-06-01falseiso4217:GBPxbrli:pure101050352025-03-31101050352026-03-31101050352025-04-012026-03-31101050352024-03-31101050352025-03-31101050352024-04-012025-03-3110105035bus:SmallEntities2025-04-012026-03-3110105035bus:AuditExempt-NoAccountantsReport2025-04-012026-03-3110105035bus:FullAccounts2025-04-012026-03-3110105035bus:PrivateLimitedCompanyLtd2025-04-012026-03-3110105035core:WithinOneYear2026-03-3110105035core:AfterOneYear2026-03-3110105035core:WithinOneYear2025-03-3110105035core:AfterOneYear2025-03-3110105035core:ShareCapital2026-03-3110105035core:SharePremium2026-03-3110105035core:RevaluationReserve2026-03-3110105035core:OtherReservesSubtotal2026-03-3110105035core:RetainedEarningsAccumulatedLosses2026-03-3110105035core:ShareCapital2025-03-3110105035core:SharePremium2025-03-3110105035core:RevaluationReserve2025-03-3110105035core:OtherReservesSubtotal2025-03-3110105035core:RetainedEarningsAccumulatedLosses2025-03-3110105035core:LandBuildings2026-03-3110105035core:PlantMachinery2026-03-3110105035core:Vehicles2026-03-3110105035core:FurnitureFittings2026-03-3110105035core:OfficeEquipment2026-03-3110105035core:NetGoodwill2026-03-3110105035core:IntangibleAssetsOtherThanGoodwill2026-03-3110105035core:ListedExchangeTraded2026-03-3110105035core:UnlistedNon-exchangeTraded2026-03-3110105035core:LandBuildings2025-03-3110105035core:PlantMachinery2025-03-3110105035core:Vehicles2025-03-3110105035core:FurnitureFittings2025-03-3110105035core:OfficeEquipment2025-03-3110105035core:NetGoodwill2025-03-3110105035core:IntangibleAssetsOtherThanGoodwill2025-03-3110105035core:ListedExchangeTraded2025-03-3110105035core:UnlistedNon-exchangeTraded2025-03-3110105035core:LandBuildings2025-04-012026-03-3110105035core:PlantMachinery2025-04-012026-03-3110105035core:Vehicles2025-04-012026-03-3110105035core:FurnitureFittings2025-04-012026-03-3110105035core:OfficeEquipment2025-04-012026-03-3110105035core:NetGoodwill2025-04-012026-03-3110105035core:IntangibleAssetsOtherThanGoodwill2025-04-012026-03-3110105035core:ListedExchangeTraded2025-04-012026-03-3110105035core:UnlistedNon-exchangeTraded2025-04-012026-03-3110105035core:MoreThanFiveYears2025-04-012026-03-3110105035core:Non-currentFinancialInstruments2026-03-3110105035core:Non-currentFinancialInstruments2025-03-3110105035dpl:CostSales2025-04-012026-03-3110105035dpl:DistributionCosts2025-04-012026-03-3110105035core:LandBuildings2025-04-012026-03-3110105035core:PlantMachinery2025-04-012026-03-3110105035core:Vehicles2025-04-012026-03-3110105035core:FurnitureFittings2025-04-012026-03-3110105035core:OfficeEquipment2025-04-012026-03-3110105035dpl:AdministrativeExpenses2025-04-012026-03-3110105035core:NetGoodwill2025-04-012026-03-3110105035core:IntangibleAssetsOtherThanGoodwill2025-04-012026-03-3110105035dpl:GroupUndertakings2025-04-012026-03-3110105035dpl:ParticipatingInterests2025-04-012026-03-3110105035dpl:GroupUndertakingscore:ListedExchangeTraded2025-04-012026-03-3110105035core:ListedExchangeTraded2025-04-012026-03-3110105035dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-04-012026-03-3110105035core:UnlistedNon-exchangeTraded2025-04-012026-03-3110105035dpl:CostSales2024-04-012025-03-3110105035dpl:DistributionCosts2024-04-012025-03-3110105035core:LandBuildings2024-04-012025-03-3110105035core:PlantMachinery2024-04-012025-03-3110105035core:Vehicles2024-04-012025-03-3110105035core:FurnitureFittings2024-04-012025-03-3110105035core:OfficeEquipment2024-04-012025-03-3110105035dpl:AdministrativeExpenses2024-04-012025-03-3110105035core:NetGoodwill2024-04-012025-03-3110105035core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3110105035dpl:GroupUndertakings2024-04-012025-03-3110105035dpl:ParticipatingInterests2024-04-012025-03-3110105035dpl:GroupUndertakingscore:ListedExchangeTraded2024-04-012025-03-3110105035core:ListedExchangeTraded2024-04-012025-03-3110105035dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-04-012025-03-3110105035core:UnlistedNon-exchangeTraded2024-04-012025-03-3110105035core:NetGoodwill2026-03-3110105035core:IntangibleAssetsOtherThanGoodwill2026-03-3110105035core:LandBuildings2026-03-3110105035core:PlantMachinery2026-03-3110105035core:Vehicles2026-03-3110105035core:FurnitureFittings2026-03-3110105035core:OfficeEquipment2026-03-3110105035core:AfterOneYear2026-03-3110105035core:WithinOneYear2026-03-3110105035core:ListedExchangeTraded2026-03-3110105035core:UnlistedNon-exchangeTraded2026-03-3110105035core:ShareCapital2026-03-3110105035core:SharePremium2026-03-3110105035core:RevaluationReserve2026-03-3110105035core:OtherReservesSubtotal2026-03-3110105035core:RetainedEarningsAccumulatedLosses2026-03-3110105035core:NetGoodwill2025-03-3110105035core:IntangibleAssetsOtherThanGoodwill2025-03-3110105035core:LandBuildings2025-03-3110105035core:PlantMachinery2025-03-3110105035core:Vehicles2025-03-3110105035core:FurnitureFittings2025-03-3110105035core:OfficeEquipment2025-03-3110105035core:AfterOneYear2025-03-3110105035core:WithinOneYear2025-03-3110105035core:ListedExchangeTraded2025-03-3110105035core:UnlistedNon-exchangeTraded2025-03-3110105035core:ShareCapital2025-03-3110105035core:SharePremium2025-03-3110105035core:RevaluationReserve2025-03-3110105035core:OtherReservesSubtotal2025-03-3110105035core:RetainedEarningsAccumulatedLosses2025-03-3110105035core:NetGoodwill2024-03-3110105035core:IntangibleAssetsOtherThanGoodwill2024-03-3110105035core:LandBuildings2024-03-3110105035core:PlantMachinery2024-03-3110105035core:Vehicles2024-03-3110105035core:FurnitureFittings2024-03-3110105035core:OfficeEquipment2024-03-3110105035core:AfterOneYear2024-03-3110105035core:WithinOneYear2024-03-3110105035core:ListedExchangeTraded2024-03-3110105035core:UnlistedNon-exchangeTraded2024-03-3110105035core:ShareCapital2024-03-3110105035core:SharePremium2024-03-3110105035core:RevaluationReserve2024-03-3110105035core:OtherReservesSubtotal2024-03-3110105035core:RetainedEarningsAccumulatedLosses2024-03-3110105035core:AfterOneYear2025-04-012026-03-3110105035core:WithinOneYear2025-04-012026-03-3110105035core:Non-currentFinancialInstrumentscore:CostValuation2025-04-012026-03-3110105035core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-04-012026-03-3110105035core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-04-012026-03-3110105035core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-04-012026-03-3110105035core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-04-012026-03-3110105035core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-04-012026-03-3110105035core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-04-012026-03-3110105035core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-04-012026-03-3110105035core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-04-012026-03-3110105035core:Non-currentFinancialInstrumentscore:CostValuation2026-03-3110105035core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2026-03-3110105035core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2026-03-3110105035core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2026-03-3110105035core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2026-03-3110105035core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2026-03-3110105035core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2026-03-3110105035core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2026-03-3110105035core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2026-03-3110105035core:Non-currentFinancialInstrumentscore:CostValuation2025-03-3110105035core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-03-3110105035core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-03-3110105035core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-03-3110105035core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-03-3110105035core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-03-3110105035core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-03-3110105035core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-03-3110105035core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-03-3110105035bus:Director12025-04-012026-03-3110105035bus:Director22025-04-012026-03-3110105035core:FurnitureFittingsToolsEquipment2025-03-3110105035core:FurnitureFittingsToolsEquipment2026-03-3110105035core:FurnitureFittingsToolsEquipment2025-04-012026-03-31

CONTEXT THERAPY LIMITED

Registered Number
10105035
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2026

CONTEXT THERAPY LIMITED
Company Information
for the year from 1 April 2025 to 31 March 2026

Directors

Dr Carlton Coulter
Dr Sophie Coulter

Registered Address

42 High Street Wanstead
London
E11 2RJ

Registered Number

10105035 (England and Wales)
CONTEXT THERAPY LIMITED
Balance Sheet as at
31 March 2026

Notes

2026

2025

£

£

£

£

Fixed assets
Intangible assets32,3604,720
Tangible assets49792,021
3,3396,741
Current assets
Debtors58,3016,570
Cash at bank and on hand98,63586,302
106,93692,872
Creditors amounts falling due within one year6(34,277)(35,384)
Net current assets (liabilities)72,65957,488
Total assets less current liabilities75,99864,229
Provisions for liabilities7(245)(505)
Net assets75,75363,724
Capital and reserves
Called up share capital300300
Profit and loss account75,45363,424
Shareholders' funds75,75363,724
The financial statements were approved and authorised for issue by the Board of Directors on 1 June 2026, and are signed on its behalf by:
Dr Carlton Coulter
Director
Registered Company No. 10105035
CONTEXT THERAPY LIMITED
Notes to the Financial Statements
for the year ended 31 March 2026

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page. The company was incorporated on 05 April 2016 and commenced trading on 01 April 2022.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Intangible assets
The acquisition goodwill has been recognised at cost less any impairment losses and being amortised over its useful life of 5 years.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Straight line (years)
Fixtures and fittings4
Office Equipment3
2.Average number of employees

20262025
Average number of employees during the year11
3.Intangible assets

Goodwill

Total

££
Cost or valuation
At 01 April 2511,80011,800
At 31 March 2611,80011,800
Amortisation and impairment
At 01 April 257,0807,080
Charge for year2,3602,360
At 31 March 269,4409,440
Net book value
At 31 March 262,3602,360
At 31 March 254,7204,720
4.Tangible fixed assets

Fixtures & fittings

Office Equipment

Total

£££
Cost or valuation
At 01 April 252,9551,4534,408
At 31 March 262,9551,4534,408
Depreciation and impairment
At 01 April 251,4779102,387
Charge for year7393031,042
At 31 March 262,2161,2133,429
Net book value
At 31 March 26739240979
At 31 March 251,4785432,021
5.Debtors: amounts due within one year

2026

2025

££
Trade debtors / trade receivables3,8012,070
Other debtors4,5004,500
Total8,3016,570
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
6.Creditors: amounts due within one year

2026

2025

££
Trade creditors / trade payables383368
Amounts owed to related parties15,85913,022
Taxation and social security18,03521,994
Total34,27735,384
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
7.Provisions for liabilities

2026

2025

££
Net deferred tax liability (asset)245505
Total245505